At Week @ , the HAM-A and SDS total scores , CGI and Q-LES-Q scores , and response and remission rates demonstrated similar improvement for vortioxetine and venlafaxine XR , with remission rates ( MADRS @ ) of @ % ( vortioxetine ) versus @ % ( venlafaxine XR ) ( LOCF ) .